Firm Finds Novel Mechanism Of Action For HIV A Hard Sell For Investors
This article was originally published in Pharmaceutical Approvals Monthly
Executives at Koronis Pharmaceuticals are finding that having a drug with a new mechanism of action in the HIV space is a hurdle when seeking financing.
You may also be interested in...
Hopes for a vaccine or cure for HIV/AIDS have been dashed before. But recent scientific advances and greater understanding of the limits of antiretroviral drugs have reignited optimism. Just don't expect VCs to get on board.
Antiretroviral combines Gilead's Truvada with J&J's Edurant for HIV, and is intended as a replacement to the existing triple combination Atripla.
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.